A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.

Chem Biol 2012 Sep;19(9):1142-51

Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland.

Lymphocyte trafficking is critically regulated by the Sphingosine 1-phosphate receptor-1 (S1P(1)), a G protein-coupled receptor that has been highlighted as a promising therapeutic target in autoimmunity. Fingolimod (FTY720, Gilenya) is a S1P(1) receptor agonist that has recently been approved for the treatment of multiple sclerosis (MS). Here, we report the discovery of NIBR-0213, a potent and selective S1P(1) antagonist that induces long-lasting reduction of peripheral blood lymphocyte counts after oral dosing. NIBR-0213 showed comparable therapeutic efficacy to fingolimod in experimental autoimmune encephalomyelitis (EAE), a model of human MS. These data provide convincing evidence that S1P(1) antagonists are effective in EAE. In addition, the profile of NIBR-0213 makes it an attractive candidate to further study the consequences of S1P(1) receptor antagonism and to differentiate the effects from those of S1P(1) agonists.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2012.07.016DOI Listing
September 2012

Publication Analysis

Top Keywords

autoimmune encephalomyelitis
8
experimental autoimmune
8
s1p1 receptor
8
s1p1 antagonist
8
potent selective
8
selective s1p1
8
s1p1
7
dosing nibr-0213
4
oral dosing
4
counts oral
4
blood lymphocyte
4
lymphocyte counts
4
therapeutic efficacy
4
fingolimod experimental
4
efficacy fingolimod
4
peripheral blood
4
comparable therapeutic
4
nibr-0213 comparable
4
antagonist induces
4
sclerosis report
4

Similar Publications